Episode 226: Superwarfarin Toxicity

Superwarfarin toxicity: recognition, reversal, and prolonged vitamin K therapy.

Hosts:
Mac Josh Reandelar, DO
Avir Mitra, MD

August 11th, 2026 Download Leave a Comment Tags:

Show Notes

Toxicology & Pathophysiology

  • Long-acting vitamin K antagonists (LA-VKAs), developed as potent rodenticides
  • Examples: brodifacoum, bromadiolone, difenacoum, chlorophacinone
  • Much more potent + far longer acting than warfarin
  • MOA: inhibits VKORC1 → ↓ vitamin K recycling → impaired γ-carboxylation
  • ↓ factors II, VII, IX, X + proteins C/S
  • Highly lipophilic → extensive tissue/fat sequestration + slow redistribution
  • Effect can persist weeks-months; occasionally much longer
  • Not dialyzable
  • Exposure: large acute ingestion OR repeated low-dose exposure
  • Source may be unclear, concealed, or initially unknown

Presentation

  • Often delayed + insidious
  • Severe coagulopathy may precede obvious bleeding
  • Early: epistaxis, gingival bleeding, bruising/ecchymoses, hematuria
  • Classic clue: well-appearing pt + extraordinarily abnormal coagulation studies
  • Severe bleeding: RP hemorrhage, ICH, spinal hemorrhage, tamponade, major GI/GU bleeding
  • RP bleed → flank/back pain ± CVA tenderness

Labs & Diagnosis

  • PT/INR: profoundly elevated, sometimes beyond assay range
  • aPTT: may also be markedly prolonged with severe factor depletion
  • CBC/plts: often initially preserved unless major blood loss/other process
  • LFTs: often relatively normal
  • Profound INR + no warfarin + preserved liver function → think superwarfarin
  • CT based on bleeding site; CT A/P for suspected RP hemorrhage
  • Confirm: specialized serum/blood testing for long-acting anticoagulants, typically chromatography/mass spec
  • Do NOT delay resuscitation/treatment for confirmatory testing

Elevated INR: Differential

  • Superwarfarin exposure
  • Warfarin toxicity
  • Severe vitamin K deficiency: malnutrition, malabsorption, prolonged abx
  • Liver failure/cirrhosis
  • DIC
  • Acquired factor deficiency/inhibitor

Helpful discriminators

  • Liver dz → abnormal hepatic profile/clinical context
  • DIC → ↓ plts, ↓ fibrinogen, ↑ D-dimer
  • No warfarin + massive INR + relatively normal LFTs/plts → superwarfarin rises on the differential

ED Management

Major/Life-Threatening Bleeding

  • Goal: replace factors NOW + restore endogenous synthesis
  • 4F-PCC = preferred factor replacement
    • Fast, predictable correction
    • Small volume
    • No thawing/type matching
  • FFP if PCC unavailable
    • Slower + large volume/TACO risk
  • Give IV vitamin K concurrently
  • PCC = immediate bridge; vitamin K = sustained factor synthesis
  • Recheck INR + clinical bleeding response
  • Repeat PCC generally not routine; reassess before redosing

No Major Bleeding, Critical INR

  • Vitamin K is primary therapy
  • High-dose PO vitamin K often preferred when clinically stable
  • Avoid unnecessary PCC/FFP if no major bleeding
  • Serial INR monitoring essential

Poison Control

  • Call early
  • Helps with:
    • Confirmatory testing
    • Vitamin K dosing
    • Duration of therapy
    • Monitoring/taper strategy
    • Outpatient planning

The Long Game

  • This is NOT standard warfarin toxicity
  • Vitamin K requirements may persist for months
  • Discharge only when bleeding controlled + clinically stable on oral regimen
  • Close serial INR follow-up mandatory
  • Slowly taper vitamin K under laboratory guidance
  • Stopping too early → rebound INR elevation + recurrent bleeding

Take Home Points

  1. Massive unexplained INR + relatively normal liver function → think superwarfarin
  2. Major bleeding → 4F-PCC + IV vitamin K
  3. Expect prolonged vitamin K therapy + meticulous INR follow-up

Leave a Reply

Your email address will not be published. Required fields are marked *